Developed & Manufactured by Biomedica

Periostin Human ELISA

Cat. No.: BI-20433

/ € 565Please Inquire

Contact distributor

Therapeutic Areas
periostin structure
Assay Characteristics
  • Category number

    BI-20433

  • Method

    Sandwich ELISA, HRPO/TMB, 12×8-well detachable strips

  • Sample type

    Serum, EDTA plasma, citrate plasma, heparin plasma

  • Sample volume

    10 µl / well

  • Assay time

    2 h / 2 h / 1 h / 30 min

  • Sensitivity

    20 pmol/l

  • Standard range

    0 – 364 000 pg/ml

    0 – 4000 pmol/l

  • Conversion factor

    1 ng/ml = 0.011 pmol/l (MW: 91 kDa)

  • Regulatory status

    Research use only.

Product details

Product Overview

The human periostin immunoassay is a 3.5 hour, 96-well sandwich ELISA for the quantitative determination of periostin in human serum and plasma. The assay employs human serum-based standards to ensure the measurement of biologically reliable data. The human periostin kit uses highly purified, epitope mapped antibodies with characterized binding kinetics. The detection antibody used in the human periostin ELISA kit binds to a linear epitope close to the N-terminus in the FAS4 domain of periostin and the polyclonal coating antibody recognizes multiple linear epitopes distributed over the periostin molecule.

Principle of the Assay

1+50 pre-diluted standard/sample/control and goat biotinylated anti-periostin antibody (AB) are pipetted into the wells of the microtiter strips, which are pre-coated with anti-human periostin antibody. periostin present in the STD/sample/CTRL binds to the pre-coated antibody in the well and forms a sandwich with the detection antibody. In a washing step all non-specific unbound material is removed.

In a second step, the streptavidin-HRPO conjugate is added. After another washing step, substrate (TMB) is pipetted into the wells. The enzyme catalyzed color change of the substrate is directly proportional to the amount of periostin. This color change is detectable with a standard microtiter plate ELISA reader. A dose response curve of the absorbance (optical density, OD at 450 nm) vs. standard concentration is generated, using the values obtained from the standard. The concentration of human periostin in the sample is determined directly from the dose response curve.

Typical Standard Curve

The figure below shows a typical standard curve for the human periostin ELISA. The immunoassay is calibrated against recombinant periostin peptide:

 

Kit components

CONT KIT COMPONENTS QUANTITY
PLATE Mouse monoclonal anti-human periostin antibody, pre-coated microtiter strips in a stripholder, packed in an aluminium bag with desiccant 12 x 8 tests
WASHBUF Wash buffer concentrate 20x, natural cap 1 x 50 ml
AB Goat polyclonal anti-human periostin antibody, biotinylated, green cap, ready to use 1 x 18 ml
STD Standards 1-7, (0, 125, 250, 500, 1000, 2000, 4000 pmol/l), white caps , lyophilised 7 vials
CTRL Control A and B, yellow cap, lyophilised (for concentration see label) 2 vials
ASYBUF Assay Buffer, red cap, ready to use 1 x 55 ml
CONJ Conjugate, (streptavidin-HRPO), amber bottle, amber cap, ready to use 1 x 18 ml
SUB Substrate (TMB solution), amber bottle, blue cap, ready to use 1 x 22 ml
STOP Stop solution, white cap, ready to use  1 x 7 ml

Storage instructions: All reagents of the human periostin ELISA kit are stable at 4°C until the expiry date stated on the label of each reagent.

Instructions for use

Sample Collection & Storage

Serum and plasma are suitable for use in this assay. We recommend duplicate measurements for all samples, standards and controls.  Do not change sample type during studies.

Collect venous blood samples by using standardized blood collection tubes for serum or plasma. Perform serum and plasma separation by centrifugation according to supplier’s instructions of the blood collection devices and measure the acquired serum or plasma samples as soon as possible. For longer storage aliquot and store at -25°C or lower. Samples are stable for 4 freeze-thaw cycles. Thawed samples should be assayed as soon as possible.  Lipemic or haemolysed samples may give erroneous results. Samples should be mixed well before assaying.

Reagent Preparation

Wash Buffer

1.

Bring the WASHBUF concentrate to room temperature (18-26°C). Crystals in the buffer concentrate will dissolve at room temperature.

2.

Dilute the WASHBUF concentrate 1:20, e.g., 50ml WASHBUF + 950ml distilled or deionized water. Only use diluted WASHBUF when performing the assay.

The diluted WASHBUF is stable up to one month at 4°C (2-8°C).

Sample Preparation

Bring samples to room temperature and mix samples gently to ensure the samples are homogenous. We recommend duplicate measurements for all samples.

 

SERUM or PLASMA Samples (human or non-human samples) and CELL CULTURE SUPERNATANTS must be diluted 1+50 with ASYBUF (assay buffer) prior to the assay, e.g. 10 µl sample + 500 µl ASYBUF. Note: 150 µl pre-diluted sample is required / well.

 

URINE Samples must be diluted at least 1+3 with ASYBUF (assaybuffer) prior to the assay, e.g. 100 µl sample + 300 µl ASYBUF. Note: 150 µl pre-diluted sample is required / well.

 

Assay Protocol

Read the entire protocol before beginning the assay.

1.

Mark positions for STD/SAMPLE/CTRL (Standard/Sample/Control) on the protocol sheet.

2.

Take microtiter strips out of the aluminum bag. Store unused strips with desiccant at 4°C in the aluminum bag. Strips are stable until expiry date stated on the label.

3.

Add 150 µl pre-diluted (1+50)* STD/CTRL/SAMPLE into the respective wells.

4.

Cover the plate tightly and incubate for 2 hours at room temperature (18-26°C).

5.

Aspirate and wash wells 5 x with 300 µl diluted WASHBUF. After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.

6.

Add 150 µl AB (biotinylated anti Periostin antibody, green cap) into each well, swirl gently.

7.

Cover tightly and incubate for 2 hours at room temperature.

8.

Aspirate and wash wells 5 x with 300 µl diluted WASHBUF. After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.

9.

Add 150 µl CONJ (Conjugate, amber cap) into each well. Swirl gently.

10.

Cover tightly and incubate for 1 hour at room temperature.

11.

Aspirate and wash wells 5 x with 300 µl diluted WASHBUF. After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.

12.

Add 150 µl SUB (substrate, blue cap) into each well.

13.

Incubate for 30 min at room temperature in the dark.

14.

Add 50 µl STOP (stop solution, white cap) into each well. Swirl gently.

15.

Measure absorbance immediately at 450 nm with reference 630 nm, if available.

Calculation of Results

Read the optical density (OD) of all wells on a plate reader using 450 nm wavelength (correction wavelength 630 nm). Construct the standard curve from the OD values of the STD. Use commercially available software or graph paper. Obtain sample concentration from this standard curve. The assay was evaluated with 4PL algorithm. Different curve fitting methods need to be evaluated by the user. Sample dilutions above 1+50 have to be considered when calculating the final sample concentration.

 

The quality control (QC) protocol supplied with the kit shows the results of the final release QC for each kit lot at production date. Data for OD obtained by customers may differ due to various influences and/or due to the normal decrease of signal intensity during shelf life. However, this does not affect validity of results as long as an OD of 1.50 or higher is obtained for the standard with the highest concentration and the values of the CTRLs are in range (target ranges see labels).

Background & Therapeutic Areas

Periostin Protein

Periostin (OSF-2) is secreted as a 91 kDa homodimeric soluble extracellular matrix protein expressed in collagen-rich fibrous connective tissues. There are at least 7 isoforms of Periostin, caused by alternative splicing (http://www.uniprot.org/uniprot/Q15063).

Molecular Weight

91 kDa

Cellular localisation

Extracellular or secreted

Post-translational modifications

Glycosylation, disulphide bonds

Sequence similarities

FAS1 superfamily

Alternative Names

POSTN, OSF-2, OSF2, PDLPN, PN

Pubchem ID

187888 link: https://pubchem.ncbi.nlm.nih.gov/compound/periostin

Genecards

POSTN link:  https://www.genecards.org/cgi-bin/carddisp.pl?gene=POSTN&keywords=periostin

OMIM

608777 link: https://www.omim.org/entry/608777

PDB

5WT7 link: http://www.rcsb.org/structure/5WT7  
5YJG link: http://www.rcsb.org/structure/5YJG
5YJH link: http://www.rcsb.org/structure/5YJH

Pfam

PF02469 link: http://pfam.xfam.org/family/PF02469  

Protein Atlas

POSTN link: https://www.proteinatlas.org/ENSG00000133110-POSTN/tissue

Uniport ID

Q15063 link: https://www.uniprot.org/uniprot/Q15063

Periostin Function

Periostin is involved in osteoblast recruitment, attachment and spreading. It has been associated with the epithelial-mesenchymal transition in cancer and with the differentiation of mesenchyme in the developing heart. Periostin has functions in osteology, tissue repair, oncology, cardiovascular and respiratory diseases, and in various inflammatory settings.

  • Metabolic Disease
    • Diabetic retinopathy (Ding et al., 2018)
  • Nephrology
    • Kidney fibrosis (An et al., 2018; Hwang et al., 2017; Mael-Ainin et al., 2014; Sen et al., 2011)
    • Polycystsic kidney disease (Raman et al., 2018; Wallace et al., 2014)
    • Hypertensive nephropathy (Guerrot et al., 2012)
    • Kidney injury (Satirapoj et al., 2015, 2014, 2012)
    • IgA Nephrophathy (Hwang et al., 2016; Satirapoj et al., 2014)
  • Oncology
    • Multiple myeloma (Terpos et al., 2016)
    • Ameloblastoma (Kang et al., 2018)
    • Ovarian cancer (Ryner et al., 2015; Sung et al., 2016; Tang et al., 2018)
    • Papillary thyroid carcinoma (Giusca et al., 2017)
    • Head and neck cancer (Liu et al., 2018)
    • Breast carcinoma (Kim et al., 2017; Lambert et al., 2016; Nuzzo et al., 2016; Ratajczak-Wielgomas et al., 2017)
    • Lung cancer (Che et al., 2017; Zhang et al., 2017)
    • Osteosarcoma (Hu et al., 2016)
    • Gastric cancer (Liu et al., 2016)
    • Bladder cancer (Silvers et al., 2016)
    • Prostate cancer (Tian et al., 2015)
  • Osteology
    • Osteoporosis (Kim et al., 2015; Rousseau et al., 2014; Varughese et al., 2018; Yan et al., 2017)
    • Paget’s disease (Polyzos et al., 2017)
    • Osteoarthritis (Chijimatsu et al., 2015; Honsawek et al., 2015b; Rousseau et al., 2014; Tajika et al., 2017)
    • Rheumatoid arthritis (Kerschan-Schindl et al., 2018; Sakellariou et al., 2015)
    • Anyklosing spondylitis (Solmaz u. a., 2018)
  • Other
    • Wound healing
    • Miscarriage (Freis et al., 2017)
    • Skin diseases (Murota et al., 2017; Sung et al., 2017)
    • Liver stiffness (Honsawek et al., 2015)
  • Respitatory disease
    • Asthma (Carpagnano et al., 2018; Górska et al., 2016; Hoshino et al., 2016; Inoue et al., 2016; Kim et al., 2014; Lee et al., 2018; Matsusaka et al., 2015; O’Dwyer and Moore, 2017; Song et al., 2015)
    • Allergy (Fujishima et al., 2016; Izuhara et al., 2017)
    • Pulmonary fibrosis (Ohta et al., 2017)
    • Bronchopulmoany dysplasia (Ahlfeld et al., 2016)

Periostin Induces Kidney Fibrosis after Acute Kidney Injury via the p38 MAPK Pathway.
An, J.N., Yang, S.H., Kim, Y.C., Hwang, J.H., Park, J.Y., Kim, D.K., Kim, J.H., Kim, D.W., Hur, D.G., Oh, Y.K., Lim, C.S., Kim, Y.S., Lee, J.P., 2018. Am. J. Physiol. Renal Physiol.

https://doi.org/10.1152/ajprenal.00203.2018

PMID: 30539653

Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?
 Carpagnano, G.E., Scioscia, G., Lacedonia, D., Soccio, P., Lepore, G., Saetta, M., Foschino Barbaro, M.P., Barnes, P.J., 2018. Chest 154, 1083–1090.
https://doi.org/10.1016/j.chest.2018.08.1032
PMID: 30336944

Increased serum periostin concentrations are associated with the presence of diabetic retinopathy in patients with type 2 diabetes mellitus.
 Ding, Y., Ge, Q., Qu, H., Feng, Z., Long, J., Wei, Q., Zhou, Q., Wu, R., Yao, L., Deng, H., 2018. J. Endocrinol. Invest. 41, 937–945.
https://doi.org/10.1007/s40618-017-0820-x
PMID: 29349642

Upregulation of Periostin expression in the pathogenesis of ameloblastoma.
 Kang, Y., Liu, J., Zhang, Y., Sun, Y., Wang, J., Huang, B., Zhong, M., 2018. Pathol. Res. Pract. 214, 1959–1965.
 https://doi.org/10.1016/j.prp.2018.08.028
PMID: 30196986

Rheumatoid arthritis in remission : Decreased myostatin and increased serum levels of periostin.
 Kerschan-Schindl, K., Ebenbichler, G., Föeger-Samwald, U., Leiss, H., Gesslbauer, C., Herceg, M., Stummvoll, G., Marculescu, R., Crevenna, R., Pietschmann, P., 2018. Wien. Klin. Wochenschr.
https://doi.org/10.1007/s00508-018-1386-0
PMID: 30171335

Serum Periostin Levels: A Potential Serologic Marker for Toluene Diisocyanate-Induced Occupational Asthma.
 Lee, J.H., Kim, S.H., Choi, Y., Trinh, H.K.T., Yang, E.M., Ban, G.Y., Shin, Y.S., Ye, Y.M., Izuhara, K., Park, H.S., 2018. Yonsei Med. J. 59, 1214–1221.
https://doi.org/10.3349/ymj.2018.59.10.1214
PMID: 30450856; PMCID: PMC6240562

Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin.
 Liu, C., Feng, X., Wang, B., Wang, X., Wang, C., Yu, M., Cao, G., Wang, H., 2018. Cancer Sci. 109, 688–698.
https://doi.org/10.1111/cas.13479
PMID: 29284199; PMCID: PMC5834805

Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease.
 Raman, A., Parnell, S.C., Zhang, Y., Reif, G.A., Dai, Y., Khanna, A., Daniel, E., White, C., Vivian, J.L., Wallace, D.P., 2018. Am. J. Physiol. Renal Physiol.
https://doi.org/10.1152/ajprenal.00246.2018
PMID: 30332313

Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment.
 Tang, M., Liu, B., Bu, X., Zhao, P., 2018. Cancer Sci. 109, 1309–1318.
https://doi.org/10.1111/cas.13567
PMID: 29527764; PMCID: PMC5980394

 

Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study.
Varughese, R., Semprini, R., Munro, C., Fingleton, J., Holweg, C., Weatherall, M., Beasley, R., Braithwaite, I., 2018. Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol. 14.
https://doi.org/10.1186/s13223-018-0254-9
PMID: 30065761; PMCID: PMC6060508

Effects of lentivirus-mediated silencing of Periostin on tumor microenvironment and bone metastasis via the integrin-signaling pathway in lung cancer.
Che, J., Shen, W.-Z., Deng, Y., Dai, Y.-H., Liao, Y.-D., Yuan, X.-L., Zhang, P., 2017. Life Sci. 182, 10–21.
https://doi.org/10.1016/j.lfs.2017.05.030
PMID: 28601389

Serum periostin levels in early in pregnancy are significantly altered in women with miscarriage.
Freis, A., Schlegel, J., Kuon, R.J., Doster, A., Jauckus, J., Strowitzki, T., Germeyer, A., 2017. Reprod. Biol. Endocrinol. RBE 15.
https://doi.org/10.1186/s12958-017-0307-9
PMID: 29096644; PMCID: PMC5667517

Heterogeneous Periostin Expression in Different Histological Variants of Papillary Thyroid Carcinoma.
Giusca, S.E., Amalinei, C., Lozneanu, L., Ciobanu Apostol, D., Andriescu, E.C., Scripcariu, A., Balan, R., Avadanei, E.R., Căruntu, I.-D., 2017. BioMed Res. Int. 2017, 8701386.
https://doi.org/10.1155/2017/8701386
PMID: 29435461; PMCID: PMC5757104

Experimental Inhibition of Periostin Attenuates Kidney Fibrosis.
Hwang, J.H., Yang, S.H., Kim, Y.C., Kim, J.H., An, J.N., Moon, K.C., Oh, Y.K., Park, J.Y., Kim, D.K., Kim, Y.S., Lim, C.S., Lee, J.P., 2017. Am. J. Nephrol. 46, 501–517.
https://doi.org/10.1159/000485325
PMID: 29268247

Periostin in inflammation and allergy.
Izuhara, K., Nunomura, S., Nanri, Y., Ogawa, M., Ono, J., Mitamura, Y., Yoshihara, T., 2017. Cell. Mol. Life Sci. CMLS 74, 4293–4303.
https://doi.org/10.1007/s00018-017-2648-0
PMID: 28887633

Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma.
Kim, G.-E., Lee, J.S., Park, M.H., Yoon, J.H., 2017. PloS One 12, e0187635.
https://doi.org/10.1371/journal.pone.0187635
PMID: 29161296; PMCID: PMC5697858

Periostin in the pathogenesis of skin diseases.
Murota, H., Lingli, Y., Katayama, I., 2017. Cell. Mol. Life Sci. CMLS 74, 4321–4328.
https://doi.org/10.1007/s00018-017-2647-1
PMID: 28916993

The role of periostin in lung fibrosis and airway remodeling.
O’Dwyer, D.N., Moore, B.B., 2017. Cell. Mol. Life Sci. CMLS 74, 4305–4314.
https://doi.org/10.1007/s00018-017-2649-z
PMID: 28918442; PMCID: PMC5659879

The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis.
Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., Kamei, A., Azuma, Y., Matsumoto, H., Yamaguchi, Y., Aihara, M., Johkoh, T., Kawaguchi, A., Ichiki, M., Sagara, H., Kadota, J.-I., Hanaoka, M., Hayashi, S.-I., Kohno, S., Hoshino, T., Izuhara, K., Consortium for Development of Diagnostics for Pulmonary Fibrosis Patients (CoDD-PF), 2017. PloS One 12, e0174547.
https://doi.org/10.1371/journal.pone.0174547
PMID: 28355256; PMCID: PMC5371347

Periostin and sclerostin levels in juvenile Paget’s disease.
 Polyzos, S.A., Makras, P., Anastasilakis, A.D., Mintziori, G., Kita, M., Papatheodorou, A., Kokkoris, P., Terpos, E., 2017. Clin. Cases Miner. Bone Metab. Off. J. Ital. Soc. Osteoporos. Miner. Metab. Skelet. Dis. 14, 269–271.
https://doi.org/10.11138/ccmbm/2017.14.2.269
PMID: 29263750; PMCID: PMC5726226

Expression of periostin in breast cancer cells.
Ratajczak-Wielgomas, K., Grzegrzolka, J., Piotrowska, A., Matkowski, R., Wojnar, A., Rys, J., Ugorski, M., Dziegiel, P., 2017. Int. J. Oncol. 51, 1300–1310.
https://doi.org/10.3892/ijo.2017.4109
PMID: 28902360

An association of periostin levels with the severity and chronicity of atopic dermatitis in children.
Sung, M., Lee, K.S., Ha, E.G., Lee, S.J., Kim, M.A., Lee, S.W., Jee, H.M., Sheen, Y.H., Jung, Y.H., Han, M.Y., 2017. Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol. 28, 543–550.
https://doi.org/10.1111/pai.12744
PMID: 28631851

Influence of Periostin on Synoviocytes in Knee Osteoarthritis.
Tajika, Y., Moue, T., Ishikawa, S., Asano, K., Okumo, T., Takagi, H., Hisamitsu, T., 2017. Vivo Athens Greece 31, 69–77.
https://doi.org/10.21873/invivo.11027
PMID: 28064223; PMCID: PMC5354150

Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women.
Yan, J., Liu, H.J., Li, H., Chen, L., Bian, Y.Q., Zhao, B., Han, H.X., Han, S.Z., Han, L.R., Wang, D.W., Yang, X.F., 2017. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 28, 2335–2341.
https://doi.org/10.1007/s00198-017-4034-z
PMID: 28382553

Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy.
Zhang, Y., Yuan, D., Yao, Y., Sun, W., Shi, Y., Su, X., 2017. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 39, 1010428317698367.
https://doi.org/10.1177/1010428317698367
PMID: 28459197

Early Elevation of Plasma Periostin Is Associated with Chronic Ventilator-Dependent Bronchopulmonary Dysplasia.
Ahlfeld, S.K., Davis, S.D., Kelley, K.J., Poindexter, B.B., 2016. Am. J. Respir. Crit. Care Med. 194, 1430–1433.
https://doi.org/10.1164/rccm.201605-0910LE
PMID: 27905846; PMCID: PMC5148145

The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases.
Fujishima, H., Okada, N., Matsumoto, K., Fukagawa, K., Igarashi, A., Matsuda, A., Ono, J., Ohta, S., Mukai, H., Yoshikawa, M., Izuhara, K., 2016. J. Allergy Clin. Immunol. 138, 459-467.e2.
https://doi.org/10.1016/j.jaci.2015.11.039
PMID: 26964692

Comparative study of periostin expression in different respiratory samples in patients with asthma and chronic obstructive pulmonary disease.

Górska, K., Maskey-Warzęchowska, M., Nejman-Gryz, P., Korczyński, P., Prochorec-Sobieszek, M., Krenke, R., 2016. Pol. Arch. Med. Wewn. 126, 124–137.
https://doi.org/10.20452/pamw.3299
PMID: 26895432

Association of airway wall thickness with serum periostin in steroid-naive asthma.
Hoshino, M., Ohtawa, J., Akitsu, K., 2016. Allergy Asthma Proc. 37, 225–230.
https://doi.org/10.2500/aap.2016.37.3945
PMID: 27178891

High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.
Hu, F., Shang, X.-F., Wang, W., Jiang, W., Fang, C., Tan, D., Zhou, H.-C., 2016. Int. J. Exp. Pathol. 97, 86–92.
https://doi.org/10.1111/iep.12171
PMID: 27028305; PMCID: PMC4840243

Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy.
Hwang, J.H., Lee, J.P., Kim, C.T., Yang, S.H., Kim, J.H., An, J.N., Moon, K.C., Lee, H., Oh, Y.K., Joo, K.W., Kim, D.K., Kim, Y.S., Lim, C.S., 2016. Am. J. Nephrol. 44, 481–492.
https://doi.org/10.1159/000452228
PMID: 27802442

Periostin as a biomarker for the diagnosis of pediatric asthma.
Inoue, T., Akashi, K., Watanabe, M., Ikeda, Y., Ashizuka, S., Motoki, T., Suzuki, R., Sagara, N., Yanagida, N., Sato, S., Ebisawa, M., Ohta, S., Ono, J., Izuhara, K., Katsunuma, T., 2016. Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol. 27, 521–526.
https://doi.org/10.1111/pai.12575
PMID: 27062336

Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells.
Lambert, A.W., Wong, C.K., Ozturk, S., Papageorgis, P., Raghunathan, R., Alekseyev, Y., Gower, A.C., Reinhard, B.M., Abdolmaleky, H.M., Thiagalingam, S., 2016. Mol. Cancer Res. MCR 14, 103–113.
https://doi.org/10.1158/1541-7786.MCR-15-0079
PMID: 26507575; PMCID: PMC4715959

Isoprenaline Induces Periostin Expression in Gastric Cancer.
Liu, G.-X., Xi, H.-Q., Sun, X.-Y., Geng, Z.-J., Yang, S.-W., Lu, Y.-J., Wei, B., Chen, L., 2016. Yonsei Med. J. 57, 557–564.
https://doi.org/10.3349/ymj.2016.57.3.557
PMID: 26996552; PMCID: PMC4800342

The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
Nuzzo, P.V., Rubagotti, A., Zinoli, L., Salvi, S., Boccardo, S., Boccardo, F., 2016. BMC Cancer 16, 95.
https://doi.org/10.1186/s12885-016-2139-y
PMID: 26872609; PMCID: PMC4752779

Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.
Silvers, C.R., Liu, Y.-R., Wu, C.-H., Miyamoto, H., Messing, E.M., Lee, Y.-F., 2016. Oncotarget 7, 23335–23345.
https://doi.org/10.18632/oncotarget.8024
PMID: 26981774; PMCID: PMC5029630

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung, P.-L., Jan, Y.-H., Lin, S.-C., Huang, C.-C., Lin, H., Wen, K.-C., Chao, K.-C., Lai, C.-R., Wang, P.-H., Chuang, C.-M., Wu, H.-H., Twu, N.-F., Yen, M.-S., Hsiao, M., Huang, C.-Y.F., 2016. Oncotarget 7, 4036–4047.
https://doi.org/10.18632/oncotarget.6700
PMID: 26716408; PMCID: PMC4826188

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
Terpos, E., Christoulas, D., Kastritis, E., Bagratuni, T., Gavriatopoulou, M., Roussou, M., Papatheodorou, A., Eleutherakis-Papaiakovou, E., Kanellias, N., Liakou, C., Panagiotidis, I., Migkou, M., Kokkoris, P., Moulopoulos, L.A., Dimopoulos, M.A., 2016. Blood Cancer J. 6, e482.

https://doi.org/10.1038/bcj.2016.90
PMID: 27716740; PMCID: PMC5098262

Expression and pathological effects of periostin in human osteoarthritis cartilage.
Chijimatsu, R., Kunugiza, Y., Taniyama, Y., Nakamura, N., Tomita, T., Yoshikawa, H., 2015. BMC Musculoskelet. Disord. 16, 215.
https://doi.org/10.1186/s12891-015-0682-3
PMID: 26289167; PMCID: PMC4545863

Elevated serum periostin is associated with liver stiffness and clinical outcome in biliary atresia.
Honsawek, S., Udomsinprasert, W., Vejchapipat, P., Chongsrisawat, V., Phavichitr, N., Poovorawan, Y., 2015a. Biomark. Biochem. Indic. Expo. Response Susceptibility Chem. 20, 157–161.
https://doi.org/10.3109/1354750X.2015.1045032
PMID: 25980529

Association of plasma and synovial fluid periostin with radiographic knee osteoarthritis: Cross-sectional study.
Honsawek, S., Wilairatana, V., Udomsinprasert, W., Sinlapavilawan, P., Jirathanathornnukul, N., 2015b. Jt. Bone Spine Rev. Rhum. 82, 352–355.
https://doi.org/10.1016/j.jbspin.2015.01.023
PMID: 25881760

Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site. Kim, B.-J., Rhee, Y., Kim, C.H., Baek, K.H., Min, Y.-K., Kim, D.-Y., Ahn, S.H., Kim, H., Lee, S.H., Lee, S.-Y., Kang, M.-I., Koh, J.-M., 2015. Bone 81, 435–441.
 https://doi.org/10.1016/j.bone.2015.08.014
PMID: 26297442

Phenotype of asthma related with high serum periostin levels.
Matsusaka, M., Kabata, H., Fukunaga, K., Suzuki, Y., Masaki, K., Mochimaru, T., Sakamaki, F., Oyamada, Y., Inoue, T., Oguma, T., Sayama, K., Koh, H., Nakamura, M., Umeda, A., Ono, J., Ohta, S., Izuhara, K., Asano, K., Betsuyaku, T., 2015. Allergol. Int. Off. J. Jpn. Soc. Allergol. 64, 175–180.
https://doi.org/10.1016/j.alit.2014.07.003
PMID: 25838094

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., Lu, S., Fuentes, E., Huw, L.-Y., Lackner, M.R., Fu, L., Amler, L.C., Bais, C., Wang, Y., 2015. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 2941–2951.
https://doi.org/10.1158/1078-0432.CCR-14-3111
PMID: 25838397

Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.
Sakellariou, G.T., Anastasilakis, A.D., Bisbinas, I., Oikonomou, D., Gerou, S., Polyzos, S.A., Sayegh, F.E., 2015. Rheumatol. Oxf. Engl. 54, 908–914.
https://doi.org/10.1093/rheumatology/keu425
PMID: 25349442

Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.
Satirapoj, B., Tassanasorn, S., Charoenpitakchai, M., Supasyndh, O., 2015. PloS One 10, e0124055.
https://doi.org/10.1371/journal.pone.0124055
PMID: 25884625; PMCID: PMC4401767

Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma.
Song, J.-S., You, J.-S., Jeong, S.-I., Yang, S., Hwang, I.-T., Im, Y.-G., Baek, H.-S., Kim, H.-Y., Suh, D.-I., Lee, H.-B., Izuhara, K., 2015. Allergy 70, 674–681.
https://doi.org/10.1111/all.12599
PMID: 25703927

Overexpression of periostin in stroma positively associated with aggressive prostate cancer.
Tian, Y., Choi, C.H., Li, Q.K., Rahmatpanah, F.B., Chen, X., Kim, S.R., Veltri, R., Chia, D., Zhang, Z., Mercola, D., Zhang, H., 2015. PloS One 10, e0121502.
https://doi.org/10.1371/journal.pone.0121502
PMID: 25781169; PMCID: PMC4362940

Association of serum periostin with aspirin-exacerbated respiratory disease.
Kim, M.-A., Izuhara, K., Ohta, S., Ono, J., Yoon, M.K., Ban, G.Y., Yoo, H.-S., Shin, Y.S., Ye, Y.-M., Nahm, D.-H., Park, H.-S., 2014. Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 113, 314–320.
https://doi.org/10.1016/j.anai.2014.06.014
PMID: 25037608

Inhibition of Periostin Expression Protects against the Development of Renal Inflammation and Fibrosis.
Mael-Ainin, M., Abed, A., Conway, S.J., Dussaule, J.-C., Chatziantoniou, C., 2014. J. Am. Soc. Nephrol. 25, 1724–1736.
https://doi.org/10.1681/ASN.2013060664
PMID: 24578131

Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study.
Rousseau, J.C., Sornay-Rendu, E., Bertholon, C., Chapurlat, R., Garnero, P., 2014. J. Clin. Endocrinol. Metab. 99, 2533–2539.
https://doi.org/10.1210/jc.2013-3893
PMID: 24628551

Urine Periostin as a Biomarker of Renal Injury in Chronic Allograft Nephropathy.
Satirapoj, B., Witoon, R., Ruangkanchanasetr, P., Wantanasiri, P., Charoenpitakchai, M., Choovichian, P., 2014. Transplant. Proc. 46, 135–140.
https://doi.org/10.1016/j.transproceed.2013.07.069

Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease.
Wallace, D.P., White, C., Savinkova, L., Nivens, E., Reif, G.A., Pinto, C.S., Raman, A., Parnell, S.C., Conway, S.J., Fields, T.A., 2014. Kidney Int. 85, 845–854.
https://doi.org/10.1038/ki.2013.488
PMID: 24284511

Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy.
Guerrot, D., Dussaule, J.-C., Mael-Ainin, M., Xu-Dubois, Y.-C., Rondeau, E., Chatziantoniou, C., Placier, S., 2012. PloS One 7, e31974.
https://doi.org/10.1371/journal.pone.0031974
PMID: 22403621; PMCID: PMC3293874

Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells.
Satirapoj, B., Wang, Y., Chamberlin, M.P., Dai, T., LaPage, J., Phillips, L., Nast, C.C., Adler, S.G., 2012. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 27, 2702–2711.
https://doi.org/10.1093/ndt/gfr670
PMID: 22167593; PMCID: PMC3471549

Periostin Is Induced in Glomerular Injury and Expressed de Novo in Interstitial Renal Fibrosis.
Sen, K., Lindenmeyer, M.T., Gaspert, A., Eichinger, F., Neusser, M.A., Kretzler, M., Segerer, S., Cohen, C.D., 2011. Am. J. Pathol. 179, 1756–1767.
https://doi.org/10.1016/j.ajpath.2011.06.002
PMID: 21854746

Validation Data

All Biomedica ELISAs are validated according to international FDA/ICH/EMEA guidelines. For more information about our validation guidelines, please refer to our quality page and published validation guidelines and literature.

1. ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology
2. EMEA/CHMP/EWP/192217/2009 Guideline on bioanalytical method validation

Calibration

The human periostin immunoassay is calibrated against recombinant human periostin peptide

Detection Limit & Sensitivity

To determine the sensitivity of the human periostin ELISA, experiments measuring the Lower Limit of Detection (LOD) and the lower limit of quantification (LLOQ) were conducted.

The LOD, also called the detection limit, is the lowest point at which a signal can be distinguished above the background signal, i.e. the signal that is measured in the absence of periostin, with a confidence level of 99%. It is defined as the mean back calculated concentration a periostin-free sample (three independent measurements) plus three times the standard deviation of the measurements.

The LLOQ, or sensitivity of an assay, is the lowest concentration at which an analyte can be accurately quantified. The criteria for accurate quantification at the LLOQ are an analyte recovery between 75 and 125% and a coefficient of variation (CV) of less than 25%. The lowest concentration of periostin, which meets both criteria, is reported as the LLOQ.

The following values were determined for the human periostin ELISA:

LOD

20 pmol/l

LLOQ

62.5 pmol/l

Precision

The precision of an ELISA is defined as its ability to measure the same concentration consistently within the same experiments carried out by one operator (within-run precision or repeatability) and across several experiments using the same samples but conducted by several operators at different locations using different ELISA lots (in-between-run precision or reproducibility).

Within-Run Precision

Within-run precision was tested by measuring the same samples 5 times within one human periostin ELISA lot. The experiment was conducted by one operator.

 

Within-Run Precision

Sample

#1

#2

n

5

5

Mean [nmol/l]

249

2008

Standard deviation [nmol/l]

7.3

52

% CV

3

3

In-Between-Run Precision

In-between-run precision was assessed by measuring the same samples 12 times within multiple human periostin ELISA lots. The measurements were carried out by multiple operators.

 

Within-Run Precision

Sample

#1

#2

n

5

5

Mean [nmol/l]

250

1996

Standard deviation [nmol/l]

11.2

111.5

% CV

4

6

Accuracy

The accuracy of an ELISA is defined as the precision with which it can recover samples of known concentrations.

 

The recovery of the periostin ELISA was measured by adding recombinant periostin to human samples containing a known concentration endogenous periostin. The % recovery of the spiked concentration was calculated as the percentage of measured compared over the expected value.

This table shows the summary of the recovery experiments in the human periostin ELISA in different sample matrices:

 

   

% Recovery

Sample Matrix

n

+500 pmol/l

+2000 pmol/l

Mean

Range

Mean

Range

Serum

7

106

88 - 127

95

91 - 105

EDTA plasma

8

98

71 - 124

83

71 - 91

Heparin plasma

7

92

84 - 104

85

75 - 96

Citrate plasma

8

102

82 - 108

91

81 - 109


Data showing recovery of periostin in human serum samples:

 

Periostin [pmol/l]

% Recovery

Sample Matrix

ID

Reference

+500 pmol/l

+2000 pmol/l

+500 pmol/l

+2000 pmol/l

Serum

s1

688

1044

2170

88

91

Serum

s2

927

1251

2270

88

90

Serum

s3

892

1417

2266

127

91

Serum

s4

881

1257

2537

97

105

Serum

s5

1138

1623

2500

126

97

Serum

s6

1009

1471

2445

118

97

Serum

s7

1107

1470

2437

100

94

 

 

 

 

Mean

106

95

 

 

 

 

Min

88

91

 

 

 

 

Max

127

105

Data showing recovery of periostin in human EDTA plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

+500 pmol/l

+2000 pmol/l

+500 pmol/l

+2000 pmol/l

EDTA plasma

e1

907

1272

2266

96

91

EDTA plasma

e2

542

1083

1980

122

85

EDTA plasma

e3

774

1272

2021

119

82

EDTA plasma

e4

784

1304

2187

124

90

EDTA plasma

e5

789

1045

2321

71

96

EDTA plasma

e6

1145

1356

2116

71

77

EDTA plasma

e7

968

1256

1917

82

72

EDTA plasma

e8

1008

1390

1921

102

71

 

 

 

 

Min

71

71

 

 

 

 

Max

124

91

Data showing recovery of periostin in human heparin plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

+500 pmol/l

+2000 pmol/l

+500 pmol/l

+2000 pmol/l

Heparin plasma

h1

815

1201

2090

97

84

Heparin plasma

h2

581

976

1878

94

79

Heparin plasma

h3

765

1099

2090

86

85

Heparin plasma

h4

808

1150

1908

89

75

Heparin plasma

h5

831

1147

2345

84

96

Heparin plasma

h6

780

1147

2067

93

84

Heparin plasma

h7

998

1391

2304

104

90

 

 

 

 

Mean

92

85

 

 

 

 

Min

84

75

 

 

 

 

Max

104

96

Data showing recovery of periostin in human citrate plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

+500 pmol/l

+2000 pmol/l

+500 pmol/l

+2000 pmol/l

Citrate plasma

c1

798

1181

2036

97

82

Citrate plasma

c2

519

956

1852

100

80

Citrate plasma

c3

671

1074

2009

97

84

Citrate plasma

c4

707

1136

1978

103

81

Citrate plasma

c5

702

1113

2535

100

109

Citrate plasma

c6

904

1332

2569

108

106

Citrate plasma

c7

914

1209

2278

82

91

Citrate plasma

c8

829

1369

2256

129

92

 

 

 

 

Mean

102

91

 

 

 

 

Min

82

81

 

 

 

 

Max

129

109

Dilution Linearity & Parallelism

Tests of dilution linearity and parallelism ensure that both endogenous and recombinant samples containing periostin behave in a dose dependent manner and are not affected by matrix effects. Dilution linearity assesses the accuracy of measurements in diluted human samples spiked with known concentrations of recombinant analyte. By contrast, parallelism refers to dilution linearity in human samples and provides evidence that the endogenous analyte behaves the same way as the recombinant one. For dilution linearity and parallelism are assessed for each sample type and are considered acceptable if the results are within 20% of the expected concentration.

Dilution linearity was assessed by serially diluting human samples spiked with 10 000 pmol/l recombinant human periostin.

The table below shows the mean recovery and range of serially diluted recombinant periostin in serum and citrate plasma. The reference value indicates the sample concentration before the spike.

 

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

1+4

1+9

1+4

1+9

Serum

s1

1001

2342

1161

106

106

Serum

s2

348

1765

956

85

92

Citrate Plasma

c1

665

1774

776

83

73

Citrate Plasma

c2

710

1918

858

90

80

 

Parallelism was assessed by serially diluting human samples containing endogenous periostin with assay buffer.

The table below shows the mean recovery and range of serially diluted endogenous periostin in several human sample matrices:

 

    % Recovery of endogenous periostin in diluted samples
   

1+1

1+3

Sample Matrix

ID

Mean

Range

Mean

Range

Serum

12

101

90 - 113

105

69 - 134

EDTA plasma

4

99

97 - 101

115

110 - 117

Heparin plasma

4

96

92 - 97

126

104 - 177

Citrate plasma

4

95

92 - 101

122

117 - 124

 

+ Show individual measurements
Data showing dilution linearity of endogenous periostin in human serum samples:
   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

1+1

1+3

1+1

1+3

Serum

s1

647

308

121

95

93

Serum

s2

1280

725

302

113

118

Serum

s3

372

186

53

100

72

Serum

s4

953

488

199

102

105

Serum

s5

1440

713

316

99

110

Serum

s6

1466

754

307

103

105

Serum

s7

603

284

83

94

69

Serum

s8

837

375

154

90

92

Serum

s9

1608

846

511

105

127

Serum

s10

1612

860

540

107

134

Serum

s11

1155

618

337

107

117

Serum

s12

1359

691

395

102

116

 

 

 

 

Mean

101

105

 

 

 

 

Min

90

69

 

 

 

 

Max

113

134

Data showing dilution linearity of endogenous periostin in human EDTA plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

1+1

1+3

1+1

1+3

EDTA plasma

e1

1468

714

431

97

117

EDTA plasma

e2

1328

669

377

101

114

EDTA plasma

e3

1222

614

359

100

117

EDTA plasma

e4

1677

826

460

98

110

 

 

 

 

Mean

99

115

 

 

 

 

Min

97

110

 

 

 

 

Max

101

117

Data showing dilution linearity of endogenous periostin in human heparin plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

1+1

1+3

1+1

1+3

Heparin plasma

h1

1031

500

268

97

104

Heparin plasma

h2

1230

597

544

97

177

Heparin plasma

h3

1251

577

342

92

109

Heparin plasma

h4

1417

682

407

96

115

 

 

 

 

96

126

Mean

 

 

 

 

92

104

Min

 

 

 

 

97

177

Max

Data showing dilution linearity of endogenous periostin in human heparin plasma samples:

   

 Periostin [pmol/l]  

% Recovery

Sample Matrix

ID

Reference

1+1

1+3

1+1

1+3

Citrate plasma

c1

999

461

309

92

124

Citrate plasma

c2

993

504

305

101

123

Citrate plasma

c3

1079

507

328

94

122

Citrate plasma

c4

1163

534

340

92

117

 

 

 

 

Mean

95

122

 

 

 

 

Min

92

117

 

 

 

 

Max

101

124

Recommendations for sample dilution
 
High measuring samples outside of the calibration range of the curve should be diluted in assay buffer (ASYBUF, provided with the kit).

Specificity

The specificity of an ELISA is defined as its ability to exclusively recognize the analyte of interest.

The specificity of the human periostin ELISA was shown by characterizing both the capture and the detection antibodies through epitope mapping and affinity measurements. In addition, the specificity of the ELISA was established through competition experiments, which measure the ability of the antibodies to exclusively bind periostin.

This assay recognizes recombinant and endogenous (natural) human periostin.

ANTIBODY BINDING SITES

The detection antibody used in the human Periostin ELISA kit binds to a linear epitope close to the N-terminus in the FAS4 domain (AA541-549) of Periostin and the polyclonal coating antibody recognizes multiple linear epitopes distributed over the Periostin molecule.

A detailed description of the localization of epitops recognized by the antibodies used in this Periostin ELISA has been published (Gadermaier E et al., Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. J Clin Lab Anal. 2018; 32(2). doi: 10.1002/jcla.22252.)

Epitop Mapping of Utilized Antibodies

Epitop mapping has been performed by Pepperprint.

Coating antibody:

The coating antibody which is a monoclonal mouse antibody binds to m_e1: KGMTSEER (AA544-551) of Q62009-1 (Isoform 1).

Detection antibody:

The detection antibody which is a polyclonal goat antibody binds to the following AA sequences of Q62009-1 (Isoform 1):

p_e1: TQHYSDVSK (AA115-123)

p_e2: EIEGKGSY (AA127-134)

p_e3: EDDLSSF (AA246-252)

p_e4: PAMT (AA672-676)

p_e5: RISTGGGE (AA738-746)

Summary:

ISOFORMS
This assay is optimized to detect all known splicing forms of human periostin.

Cross-Reactivity

Due to the high sequence homology between human periostin and periostin of other species, the antibodies utilized in the assay may cross react with mouse, rat, cynomolgous monkey, dog and cat-periostin.

Sample Stability

Sample preparation
We recommend separating plasma or serum by centrifugation as soon as possible, e.g. 20 min at 2,000 x g, preferably at 4°C (2-8°C). Samples can be stored at 4°C (2-8°C) overnight. For long term storage, aliquot the acquired plasma or serum samples and store at -25°C or lower.

Freeze-thaw stability
The stability of endogenous periostin was tested by comparing periostin measurements in samples that had undergone four freeze-thaw cycles. The mean recovery of sample concentration after four freeze-thaw cycles is 96%.

 

    Mean % Recovery

Sample types

n

Reference

2 x F/T

3 x F/T

4 x F/T

Serum

4

100

100

103

98

EDTA plasma

4

100

91

93

90

Citrate plasma

4

100

93

91

97

Heparin plasma

4

100

96

96

99

 

 

 

 

Mean

96

Samples can be subjected to 4 freeze-thaw cycles.

Sample Values

Serum and Plasma Periostin Values in Apparently Healthy Donors
To provide expected values for circulating periostin, a panel of samples from apparently healthy donors was tested.

A summary of the results is shown below:

   

Periostin [pmol/l]

Sample types

n

Median

Range

Serum

24

864

397 – 1466

EDTA plasma

20

817

532 – 1109

Citrate plasma

20

891

569 – 1194

Heparin plasma

24

885

321 - 1407

We recommended establishing the normal range for each laboratory.

Periostin Values in Asthma and Cardiovascular Disease panels

In addition to samples from apparently healthy donors, a panel of samples from asthma and cardiovascular disease cohorts were tested.

The results of the experiments are shown below.

   

Periostin [pmol/l]

Sample types

n

Median

Range

Control

18

586

165 – 840

Asthma Cohort*

10

451

241 - 1266

Cardio Cohort*

10

867

260 - 1521

*commercially available cohort (Seralab)

Matrix Comparison

Correlation of Serum and Plasma Samples from Apparently Healthy Individuals

14 samples of apparently healthy individuals were prepared as serum and plasma pairs each deriving from one donor. Samples were assayed, and the concentrations of the samples were compared.

 

 

 Periostin [pmol/l]  

 

Donor Sample ID

Serum

Citrate plasma

EDTA plasma

Heparin plasma

CV (%)

#1

1297

1081

1243

1195

7

#2

1303

1087

1267

1345

8

#3

1710

1337

1514

1512

9

#4

1946

1775

1899

2251

9

#5

1539

1273

1392

1108

12

#6

2279

1906

2265

2316

8

#7

1901

1636

1825

1712

6

#8

1879

1678

1822

2028

7

#9

2295

1890

2026

2102

7

#10

1572

1425

1520

1760

8

#11

801

669

749

788

7

#12

1013

883

1039

806

10

#13

915

796

965

881

7

#14

941

794

992

894

8

 

 

 

 

Mean

8

 

Citations

Powered by BizGenius
Reviews
4 Reviews
Sort by:
Submit a Review

  • With image

    28 February, 2024

    Image test

    grandiz (store manager) –

  • Test Title

    31 January, 2019

    Third review

    Test –

  • Second review

    31 January, 2019

    My Review

    grandiz (store manager) –

  • First Title

    31 January, 2019

    First review

    Vlad –

Add a review

Your email address will not be published. Required fields are marked *


Downloads

Cat. No.: BI-20433

/ € 565Please Inquire

Contact distributor

Request more information


Contact Us

Phone Head Office: +4312910711 Phone Product Support: +4312910745
img